Sangamo Therapeutics (NASDAQ:SGMO) Earns Buy Rating from HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $10.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 387.80% from the stock’s current price. HC Wainwright also issued estimates for Sangamo Therapeutics’ FY2028 earnings at $0.64 EPS.

A number of other research analysts also recently commented on the stock. StockNews.com began coverage on shares of Sangamo Therapeutics in a research note on Sunday, July 28th. They set a “sell” rating for the company. Barclays upped their price target on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday.

Sangamo Therapeutics Stock Down 4.7 %

Shares of NASDAQ:SGMO opened at $2.05 on Thursday. The company has a market cap of $427.67 million, a P/E ratio of -2.73 and a beta of 1.10. The business has a fifty day simple moving average of $1.33 and a 200-day simple moving average of $0.86. Sangamo Therapeutics has a 52 week low of $0.30 and a 52 week high of $3.18.

Hedge Funds Weigh In On Sangamo Therapeutics

A number of large investors have recently modified their holdings of SGMO. Renaissance Technologies LLC increased its position in Sangamo Therapeutics by 58.8% during the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock worth $1,479,000 after purchasing an additional 1,528,600 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Sangamo Therapeutics in the first quarter worth $331,000. Geode Capital Management LLC raised its stake in shares of Sangamo Therapeutics by 14.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock valued at $1,853,000 after acquiring an additional 272,123 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Sangamo Therapeutics during the 2nd quarter valued at $89,000. Finally, Vontobel Holding Ltd. boosted its position in Sangamo Therapeutics by 412.3% during the 3rd quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock worth $259,000 after purchasing an additional 241,440 shares during the period. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.